The delivery system is based on the controlled release of the active ingredient and its progressive absorption through the buccal mucosa, avoiding abrupt plasma peaks and enabling more predictable exposure profiles. This approach allows fine control of release kinetics from a solid oral pharmaceutical dosage form.
The platform enables precise and reproducible dosing by integrating the active ingredient into a pharmaceutical matrix designed to meet criteria of uniformity and dose control. The chewable format is conceived as a pharmaceutical vehicle aimed at standardization and its use in regulated clinical environments.
Beyond the format itself, the system is developed as a drug delivery platform intended for integration into clinical and pharmaceutical development programs. The design prioritizes quality, reproducibility and compatibility with regulatory requirements, facilitating its use in clinical studies and in collaborations with the pharmaceutical industry.
Medical Flowers Developments collaborates with pharmaceutical and biotech companies interested in cannabinoid clinical trials. The company maintains an open approach to professional discussions focused on development, innovation, and investment in regulated projects.
